Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR(R) Treatment
Endocrinology and Metabolism
;
: 213-216, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-59162
ABSTRACT
We report here on a 34-year-old Korean woman with active acromegaly and who received Octreotide-LAR(R) for 12 months following transsphenoidal pituitary surgery. During Octreotide-LAR(R) treatment, the clinical improvement was paralleled with the decrease of the growth hormone levels to 1.1 ng/mL and the insulin-like growth factor-I (IGF-I) levels to 345.5 ng/mL. Octreotide-LAR(R) was discontinued when the patient was found to be at the 12th week of pregnancy. During pregnancy, the patient experienced clinical well-being and she maintained her IGF-I levels within the normal range for her age-matched despite discontinuation of Octreotide-LAR(R) treatment at early gestation. She delivered a full-term healthy male infant. The serum IGF-I levels of the patient increased progressively increased after delivery. This report describes a successful pregnancy in an acromegalic woman who was exposed to Octreotide-LAR(R) during the early gestational period. She and who showed an unexpected pattern of persistently normal IGF-I levels through the pregnancy despite discontinuation of Octreotide-LAR(R) therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Valores de Referencia
/
Acromegalia
/
Factor I del Crecimiento Similar a la Insulina
/
Hormona del Crecimiento
/
Octreótido
Límite:
Adulto
/
Femenino
/
Humanos
/
Lactante
/
Masculino
/
Embarazo
Idioma:
Inglés
Revista:
Endocrinology and Metabolism
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS